JPH0466528A - Fatty oil composition for inflammatory intestinal disease - Google Patents
Fatty oil composition for inflammatory intestinal diseaseInfo
- Publication number
- JPH0466528A JPH0466528A JP17488590A JP17488590A JPH0466528A JP H0466528 A JPH0466528 A JP H0466528A JP 17488590 A JP17488590 A JP 17488590A JP 17488590 A JP17488590 A JP 17488590A JP H0466528 A JPH0466528 A JP H0466528A
- Authority
- JP
- Japan
- Prior art keywords
- linolenic acid
- inflammatory intestinal
- oil
- oil composition
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- 230000002757 inflammatory effect Effects 0.000 title abstract 3
- 208000028774 intestinal disease Diseases 0.000 title abstract 3
- 239000010685 fatty oil Substances 0.000 title 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 30
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 15
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 15
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims abstract description 6
- 235000020778 linoleic acid Nutrition 0.000 claims abstract description 6
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 6
- 235000019197 fats Nutrition 0.000 claims description 9
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 8
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 235000015097 nutrients Nutrition 0.000 abstract description 2
- 229960004232 linoleic acid Drugs 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 239000003925 fat Substances 0.000 description 8
- 235000004347 Perilla Nutrition 0.000 description 7
- 241000229722 Perilla <angiosperm> Species 0.000 description 7
- 238000011282 treatment Methods 0.000 description 5
- 208000011231 Crohn disease Diseases 0.000 description 3
- 238000011903 nutritional therapy Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- -1 etc. Substances 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 208000010758 granulomatous inflammation Diseases 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野］
本発明は、炎症性腸疾患の治療効果を有する油脂組成物
に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to an oil and fat composition having a therapeutic effect on inflammatory bowel diseases.
〔従来の技術］
炎症性腸疾患とは、今日では原因不明の潰瘍性大腸炎と
クローン病の２つの疾患をさす。[Prior Art] Inflammatory bowel disease refers to two diseases of unknown cause today: ulcerative colitis and Crohn's disease.
潰瘍性大腸炎は、大腸とくに直腸の主として粘膜をおか
し、しばしばびらんや潰瘍を形成する疾患であり、クロ
ーン病は、消化管のどの部分にも起こり得る、線維化や
潰瘍を伴う肉芽腫性炎症性病変であり、経過が長く難治
性である。Ulcerative colitis is a disease that affects the mucous membranes of the large intestine, especially the rectum, often forming erosions and ulcers, while Crohn's disease is a granulomatous inflammation accompanied by fibrosis and ulcers that can occur in any part of the gastrointestinal tract. It is a sexual lesion that has a long course and is difficult to treat.
炎症性腸疾患の治療は、外科治療と内科治療により行な
われるが、手術後の再発が多いことから、内科治療が主
体となっている。内科治療は、薬物療法と栄養療法に大
別される。薬物療法では、ステロイド剤、Ｓ Ａ Ｓ
Ｐ （ｓａｌａｚｏｓｕｌｆａｐｙｒｉｄｉｎｅ）、免
疫抑制剤などが用いられるが、いずれも副作用が強い。Treatment for inflammatory bowel disease includes surgical and medical treatments, but as recurrence after surgery is common, medical treatment is the main treatment. Internal medicine treatment is broadly divided into drug therapy and nutritional therapy. For drug therapy, steroids, S.A.S.
P (salazosulfapyridine), immunosuppressants, etc. are used, but both have strong side effects.
栄養療法は、静脈栄養法または経腸栄養法により行なわ
れ、腸管を刺激しないことが重要である。静脈栄養法で
は、糖類、アミノ酸、電解質、ビタミン類を含む高カロ
リー輸液を経静脈的に行なうが、副作用が起こるので注
意が必要とされでいる。また、経腸栄養法は、アミノ酸
を窒素源とし、脂肪をほとんど含まない成分栄養剤が中
心であるが、長期投与の場合には脂肪乳剤を静脈投与し
なければならない。Nutritional therapy is performed by parenteral or enteral nutrition, and it is important not to irritate the intestinal tract. In parenteral nutrition, high-calorie infusions containing sugars, amino acids, electrolytes, and vitamins are administered intravenously, but caution is required as side effects may occur. In addition, enteral nutrition mainly uses component nutrients that use amino acids as a nitrogen source and contain almost no fat, but in the case of long-term administration, fat emulsions must be administered intravenously.
一方、α−リノレン酸は、いろいろな機能が見出されて
おり、例えば、アレルギー症、血栓症、高血圧症の予防
効果を有すること（特開昭６３３６７４４号公報参照）
、老齢時の脳卒中発作又は識別能低下を抑制さセること
（特開昭６４３１１７号公報参照）、腫腸細胞の転移を
抑制させること（特開昭６３−１５４６２６号公報参照
）、などがある。On the other hand, α-linolenic acid has been found to have various functions, including the ability to prevent allergies, thrombosis, and hypertension (see JP-A-6336744).
, suppressing stroke attacks or decline in discrimination ability in old age (see JP-A-643-117), suppressing metastasis of tumor cells (see JP-A-63-154,626), etc. .
本発明は、炎症性腸疾患の治療のうち、栄養療法におい
て、その症状の治療効果を増強する組成物の開発を課題
とする。An object of the present invention is to develop a composition that enhances the therapeutic effect of inflammatory bowel disease symptoms in nutritional therapy.
本発明者らは、α−リノレン酸を含有する油脂組成物が
炎症性腸疾患の治療効果を増強することを見い出し、本
発明を完成するに到った。The present inventors have discovered that an oil and fat composition containing α-linolenic acid enhances the therapeutic effect on inflammatory bowel disease, and have completed the present invention.
本発明に係る油脂組成物は、α−リノレン酸と必須脂肪
酸であるリノール酸を含みリノール酸とα−リノレン酸
との重量比が１：３以上であることを特徴としている。The oil and fat composition according to the present invention is characterized in that it contains α-linolenic acid and linoleic acid, which is an essential fatty acid, and the weight ratio of linoleic acid and α-linolenic acid is 1:3 or more.
さらに、本発明乙こおいては、α−リノレン酸を少なく
とも４０重重量以北含むことが好ましい。Furthermore, in the present invention, it is preferable that α-linolenic acid is contained at least 40% by weight.
これらの油脂組成物は、植物より得られるペリラ油（シ
ソ油）、アマニ油、エゴマ油などの油脂に含まれている
。例えば、ペリラ油の油脂組成は、α−リノレン酸を５
０〜６０％、リノール酸を１２〜１７％含んでいる。ま
た、本発明においては、このようなペリラ油に限らず、
オリーブ油、サフラワー油、コーン油、月見草油などを
適宜組み合わせて用いることも可能である。These oil and fat compositions are contained in oils and fats obtained from plants, such as perilla oil (perilla oil), linseed oil, and perilla oil. For example, the fat composition of perilla oil contains 5 α-linolenic acid.
It contains 0-60% and 12-17% linoleic acid. In addition, in the present invention, not only such perilla oil but also
It is also possible to use appropriate combinations of olive oil, safflower oil, corn oil, evening primrose oil, and the like.
本発明においては、α−リノレン酸として１日当り３〜
６ｇとなるように数回に分けて摂取するとよい。この摂
取量は、患者の症状、体重等により調整する。投与方法
としては、経口投与が適しているが、非経口、経腸など
の投与でもよい。In the present invention, the amount of α-linolenic acid is 3 to 30% per day.
It is best to divide the intake into several doses so that the total amount is 6g. This intake amount is adjusted depending on the patient's symptoms, body weight, etc. As for the administration method, oral administration is suitable, but parenteral administration, enteral administration, etc. may also be used.
経口投与の場合は、従来の添加物、例えば、シロツプ、
アラビアゴム、ソルビトールなどを含むことができ、ま
た、α−リノレン酸の酸化による変質を防ぐため、抗酸
化剤を添加することができる。For oral administration, conventional additives such as syrup,
It may contain gum arabic, sorbitol, etc., and an antioxidant may be added to prevent deterioration of α-linolenic acid due to oxidation.
次に、本発明を実施例により詳しく説明する。 Next, the present invention will be explained in detail with reference to examples.
実施例１゜
クローン病の、愚者５名に、α−リノレン酸を多量に含
むペリラ油（α−リノレン酸５６％；リノール酸１４．
５％）を２５０■のゼラヂンカプセル化し、６ｇ７７Ｈ
の量で２週間投与した。Example 1 Five patients with Crohn's disease were given perilla oil containing a large amount of α-linolenic acid (56% α-linolenic acid; 14% linoleic acid).
5%) was encapsulated in 250μ of geladine, and 6g77H
was administered for two weeks.
ペリラ油の投与前後において、炎症性腸疾患における炎
症の重要なメデイエータ−物質であるＬＴＢ、（口・イ
コトリエン）を測定した。Before and after administration of perilla oil, LTB (oral icotrienes), which is an important mediator substance of inflammation in inflammatory bowel disease, was measured.
結果を表−１に示す。The results are shown in Table-1.
表−１
〔発明の効果〕
本発明により、炎症性腸疾患に対し、治療効果を有する
油脂組成物が従供される。Table 1 [Effects of the Invention] According to the present invention, an oil and fat composition having a therapeutic effect on inflammatory bowel diseases is provided.
Claims (2)
、リノール酸とα−リノレン酸の重量比が１：３以上で
あることを特徴とする炎症性腸疾患用油脂組成物。(1) An oil and fat composition for inflammatory bowel diseases, which contains at least α-linolenic acid and linoleic acid, and has a weight ratio of linoleic acid and α-linolenic acid of 1:3 or more.
ある請求項１記載の組成物。2. The composition of claim 1, wherein the content of alpha-linolenic acid is at least 40% by weight.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17488590A JP2836206B2 (en) | 1990-07-02 | 1990-07-02 | Oil composition for inflammatory bowel disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17488590A JP2836206B2 (en) | 1990-07-02 | 1990-07-02 | Oil composition for inflammatory bowel disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0466528A true JPH0466528A (en) | 1992-03-02 |
| JP2836206B2 JP2836206B2 (en) | 1998-12-14 |
Family
ID=15986372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP17488590A Expired - Lifetime JP2836206B2 (en) | 1990-07-02 | 1990-07-02 | Oil composition for inflammatory bowel disease |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2836206B2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995026646A1 (en) * | 1994-04-01 | 1995-10-12 | Abbott Laboratories | Nutritional product for treatment of ulcerative colitis and use thereof |
| JP2008106011A (en) * | 2006-10-26 | 2008-05-08 | National Institute Of Advanced Industrial & Technology | Inflammatory cytokine production inhibitor |
| US8383678B2 (en) | 2004-02-13 | 2013-02-26 | Chrysalis Pharma Ag | Type a gelatin capsule containing PUFA in free acid form |
-
1990
- 1990-07-02 JP JP17488590A patent/JP2836206B2/en not_active Expired - Lifetime
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995026646A1 (en) * | 1994-04-01 | 1995-10-12 | Abbott Laboratories | Nutritional product for treatment of ulcerative colitis and use thereof |
| US8383678B2 (en) | 2004-02-13 | 2013-02-26 | Chrysalis Pharma Ag | Type a gelatin capsule containing PUFA in free acid form |
| US9012501B2 (en) | 2004-02-13 | 2015-04-21 | Chrysalis Pharma Ag | Type A gelatin capsule containing PUFA in free acid form |
| US9132112B2 (en) | 2004-02-13 | 2015-09-15 | Chysalis Pharma Ag | Type A gelatin capsule containing PUFA in free acid form |
| JP2008106011A (en) * | 2006-10-26 | 2008-05-08 | National Institute Of Advanced Industrial & Technology | Inflammatory cytokine production inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2836206B2 (en) | 1998-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Verma et al. | PolymericVersusElemental Diet As Primary Treatment in Active Crohn's Disease: A Randomized, Double-Blind Trial | |
| JP2010100655A (en) | Composition and method for treatment of gastro-intestinal tract of inflammatory condition | |
| JP2010100655A6 (en) | Composition and method for the treatment of inflammatory gastrointestinal tract | |
| TWI280136B (en) | Composition containing dipeptide of histidine and alanine for reducing uric acid | |
| CN110167637A (en) | 3-hydroxybutyrate glyceride is used for cephalagra management | |
| KR20030016306A (en) | Therapeutic combinations of fatty acids | |
| JP4986321B2 (en) | Methods and compositions for the treatment of inflammatory conditions | |
| HUE028065T2 (en) | Compositions for the treatment of neurologic disorders | |
| RU2005107416A (en) | EICO-PENTAIDIC ACID (EPA) FOR THE TREATMENT OF NERVO-PSYCHIC ANOREXIA (ON) AND BULIMIA | |
| Gerolami et al. | Controlled trial of chenodeoxycholic therapy for radiolucent gallstones: A multicenter study | |
| JP6775419B2 (en) | Composition for prevention or improvement of peripheral neuropathy | |
| JPH04290822A (en) | Allergy preventing medicine and food | |
| US8728546B1 (en) | Medicament for treatment of cancer, cardiovascular diseases and inflammation | |
| JP4394174B2 (en) | Inflammatory bowel disease treatment | |
| JPH09291299A (en) | Antiallergic oil and fat composition and use | |
| JPH0466528A (en) | Fatty oil composition for inflammatory intestinal disease | |
| JPH04152861A (en) | Nutrient composition for nutrition | |
| EP1498119B1 (en) | Use of conjugated linoleic acid for treating colds | |
| JP7294147B2 (en) | Composition for prevention or amelioration of nociceptive pain | |
| CN115916152A (en) | Parenteral nutritional formulation | |
| JPH06271464A (en) | Arachidonic acid-containing composition for prevention or improvement of alimentary disorder | |
| RU2564907C1 (en) | Method of treating patients with lichen planus | |
| RU2657812C2 (en) | Method for treatment of skin manifestations of a scleroderma | |
| DE2820899C2 (en) | ||
| Bhatted et al. | Ayurveda management of Palmoplantar Psoriasis (Vipadika)-a case report |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101009 Year of fee payment: 12 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101009 Year of fee payment: 12 |